z-logo
open-access-imgOpen Access
Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
Author(s) -
Nils Welsh
Publication year - 2022
Publication title -
upsala journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.808
H-Index - 41
eISSN - 2000-1967
pISSN - 0300-9734
DOI - 10.48101/ujms.v127.8841
Subject(s) - imatinib , medicine , imatinib mesylate , tyrosine kinase inhibitor , tyrosine kinase , function (biology) , diabetes mellitus , beta (programming language) , cell , cancer research , disease , pharmacology , bioinformatics , microbiology and biotechnology , endocrinology , receptor , biology , biochemistry , cancer , computer science , programming language , myeloid leukemia

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom